What are the most common mistakes with IGF-1 DES?
The most common IGF-1 DES mistakes are treating it as IGF-1 LR3 equivalent (different kinetics); running longer than 4 weeks; dosing fasted (hypoglycemia). Most issues people run into come down to protocol and expectations, not the compound itself. Going in informed matters here because human evidence for IGF-1 DES is limited.
Common IGF-1 DES mistakes
- Treating it as IGF-1 LR3 equivalent (different kinetics)
- Running longer than 4 weeks
- Dosing fasted (hypoglycemia)
Bloodwork worth tracking
- Fasting glucose every 2 weeks
- IGF-1 baseline
References
- Insulin-like growth factor-I (IGF-I) and especially IGF-I variants are anabolic in dexamethasone-treated rats — Tomas FM, Knowles SE, Owens PC, et al., Biochemical Journal, 1992
- Mechanisms of IGF-1-Mediated Regulation of Skeletal Muscle Hypertrophy and Atrophy — Yoshida T & Delafontaine P, Cells, 2020
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on IGF-1 DES
Last updated 2026-06-15.